<DOC>
	<DOCNO>NCT00701558</DOCNO>
	<brief_summary>This single arm study ass efficacy safety erlotinib + gemcitabine chemotherapy-naive participant unresectable , advanced and/or metastatic non-small cell lung cancer . Participants receive erlotinib 150 mg orally ( po ) daily , combination gemcitabine 1000 mg/m^2 intravenously ( iv ) weekly 3 week 4 week cycle . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study First Line Treatment With Tarceva ( Erlotinib ) Combination With Gemcitabine Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; advanced and/or metastatic ( stage IIIB/IV ) unresectable nonsmall cell lung cancer ; previous systemic chemotherapy , radiation therapy immunotherapy ; Eastern Cooperative Oncology Group ( ECOG ) &gt; =2 . prior systemic antitumor therapy human epidermal growth factor receptor 1 ( HER1/EGFR ) inhibitor ; active , noncontrolled systemic disease ; malignancy within 5 year ( except adequately treated cancer situ cervix , basal squamous cell skin cancer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>